More Than Doubling of Costs With Unchanged 12-Month Mortality in Incident Metastatic Prostate Cancer in Germany, 2011–2024

Written By Winnie Wu

Costs more than doubled, survival unchanged: new ISPOR 2026 poster on metastatic prostate cancer in Germany

Using anonymized German statutory health insurance claims data from 2011 to 2024, the GIPAM team analysed 12-month overall survival and inflation-adjusted healthcare costs in 14 annual cohorts of patients with incident metastatic prostate cancer (mPC).

Age-standardized 12-month survival remained nearly unchanged (91.0% in 2011 vs. 91.2% in 2024), while costs per patient more than doubled from €17,913 to €36,327. Spending shifted strongly from inpatient care to outpatient drugs, whose share of total costs rose from 28.9% to 53.5%.

Learn more about the poster below.

Learn more
Winnie Wu
Previous

Increasing Costs and Limited Mortality Improvement in Incident Metastatic Lung Cancer in German Statutory Health Insurance Claims, 2011–2024
Next

Epidemiology, Clinical Burden and Inflammatory Marker Testing in Atherosclerotic Cardiovascular Disease and Symptomatic Heart Failure in Germany: Insights from the ACHILLES Claims Data Analysis